Fecal Microbiota Transplantation (FMT) Market Report 2024

This Fecal Microbiota Transplantation (FMT) market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The fecal microbiota transplantation (FMT) market size has grown strongly in recent years. It will grow from $0.8 billion in 2023 to $0.85 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth during the historic period can be attributed to a rising awareness of the gut microbiome, expanding therapeutic applications, the growth of personalized medicine, adoption in gastroenterology practices, a higher number of clinical trials, and increased funding and investments.

The fecal microbiota transplantation (FMT) market size is expected to see strong growth in the next few years. It will grow to $1.12 billion in 2028 at a compound annual growth rate (CAGR) of 7%. The growth during the forecast period can be attributed to the rising incidence of Clostridium difficile infections (CDI), an increasing prevalence of inflammatory bowel diseases, heightened research and development activities, a growing geriatric population, and expanding healthcare infrastructure. Key trends during this period include the creation of standardized protocols for donor screening and stool preparation, advancements in microbiome analysis, improved stool processing technologies, innovative delivery methods, and the development of synthetic or standardized microbiota-based products.

The increasing incidence of gastrointestinal disorders is anticipated to fuel the expansion of the fecal microbiota transplantation (FMT) market in the future. Gastrointestinal (GI) disorders encompass a variety of conditions that impact the gastrointestinal tract, which includes the esophagus, stomach, small intestine, large intestine (colon), rectum, and anus. Factors contributing to the rise in GI disorders include heightened stress levels, sedentary habits, and a greater intake of processed foods. Fecal microbiota transplantation is utilized to restore healthy gut bacteria in patients with gastrointestinal disorders, particularly for the treatment of recurrent Clostridioides difficile infections. For example, Crohn's and Colitis Canada, a non-profit organization, reported that the number of individuals with inflammatory bowel disease (IBD) in Canada is rapidly increasing, projected to rise from 322,600 in 2023 (0.8% of the population) to 470,000 by 2035 (1.1% of the population). In 2023, 11,000 new cases are expected to be diagnosed (approximately one every 48 minutes), with this number increasing to 14,000 by 2035 (approximately one every 38 minutes). Consequently, the growing prevalence of gastrointestinal disorders is a significant factor driving the growth of the fecal microbiota transplantation (FMT) market.

Leading companies in the fecal microbiota transplantation (FMT) market are concentrating on developing innovative solutions, such as microbiota-based live biotherapeutics, to improve treatment effectiveness for gastrointestinal disorders. Microbiota-based live biotherapeutics involve using live microorganisms as therapeutic agents to restore or alter the gut microbiome for treating various diseases. For example, in November 2022, Ferring Pharmaceuticals, a biopharmaceutical company based in Switzerland, received approval from the US Food and Drug Administration (FDA) for REBYOTA (fecal microbiota, live-jslm). This novel, first-in-class microbiota-based live biotherapeutic is designed to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals aged 18 and older, following antibiotic treatment for recurrent CDI. REBYOTA is specifically indicated for preventing the recurrence of Clostridioides difficile (C. difficile) infection in this age group after such treatment.

In October 2022, SYNLAB Group, a Germany-based provider of medical diagnostic services, formed a partnership with Microba to improve access to advanced microbiome analysis and enhance patient health management. The collaboration aims to expand the availability of the myBIOME test across Europe and Latin America, building on its success in Spain and Colombia. Microba, an Australia-based biotechnology company, specializes in fecal microbiota transplantation (FMT) research and application.

Major companies operating in the fecal microbiota transplantation (FMT) market are Ferring Pharmaceuticals, Johns Hopkins Medicine, Seres Therapeutics, Taconic Biosciences, Enterome, Rebiotix Inc, Finch Therapeutics Group Inc, Locus Biosciences, Yeda Research and Development Co. Ltd, Microbiotica Limited, CosmosID Inc, AOBiome, Synthetic Biologics Inc., Osel Inc., OpenBiome, Asia Microbiota Bank, Taymount Clinic, MicroBiome Therapeutics LLC, MaaT Pharma SA, Kallyope.

North America was the largest region in the fecal microbiota transplantation (FMT) market in 2023. The regions covered in the fecal microbiota transplantation (FMT) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fecal microbiota transplantation (FMT) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Fecal microbiota transplantation (FMT) is a medical procedure where a healthy donor's fecal material is transplanted into a recipient's gastrointestinal tract to restore the balance of beneficial microorganisms in the gut. This procedure is typically used to treat conditions where the gut microbiota is disrupted, such as recurrent clostridium difficile infection (CDI) that does not respond to standard treatments.

The main types of fecal microbiota transplantation (FMT) are fermentation, fresh, and cryopreservation. Fermentation in Fecal Microbiota Transplantation (FMT) refers to the process by which gut bacteria break down complex carbohydrates and fibers in the gastrointestinal tract, producing short-chain fatty acids and other metabolites that promote gut health. Donor types include stool-derived, fecal-derived, and whole-microbiome derived, used to treat various conditions such as Clostridioides difficile infection, inflammatory bowel disease, metabolic syndrome, and others. It is administered through oral, rectal, nasogastric, and colon capsule routes. The end users include hospitals, specialty clinics, and others.

The fecal microbiota transplantation (FMT) market research report is one of a series of new reports that provides fecal microbiota transplantation (FMT) market statistics, including the fecal microbiota transplantation (FMT) industry's global market size, regional shares, competitors with a fecal microbiota transplantation (FMT) market share, detailed fecal microbiota transplantation (FMT) market segments, market trends and opportunities, and any further data you may need to thrive in the fecal microbiota transplantation (FMT) industry. This fecal microbiota transplantation (FMT) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fecal microbiota transplantation (FMT) market consists of revenues earned by entities by providing services such as donor screening and testing, microbiome assessment, stool collection, processing and preparation, endoscopic delivery, clinical monitoring, and symptom management. The market value includes the value of related goods sold by the service provider or included within the service offering. The fecal microbiota transplantation (FMT) market also includes sales of oral capsules, colonoscopy-based FMT, nasogastric or nasoduodenal tube and lyophilized (freeze-dried) stool. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.